Cargando…

Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials

OBJECTIVES: The risk of recurrent Clostridium difficile infections (RCDIs) is high when treated with standard antibiotics therapy (SAT) alone. It is suggested that the addition of faecal microbiota transplantation (FMT) or bezlotoxumab after SAT reduces the risk of RCDI. In the absence of head-to-he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alhifany, Abdullah A, Almutairi, Abdulaali R, Almangour, Thamer A, Shahbar, Alaa N, Abraham, Ivo, Alessa, Mohammed, Alnezary, Faris S, Cheema, Ejaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Infectious Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858162/ https://www.ncbi.nlm.nih.gov/pubmed/31699731 http://dx.doi.org/10.1136/bmjopen-2019-031145

Ejemplares similares

Assessing Galleria mellonella as a preliminary model for systemic Staphylococcus aureus infection: Evaluating the efficacy and impact of vancomycin and Nigella sativa oil on gut microbiota
por: Alnezary, Faris S., et al.
Publicado: (2023)

Hemophagocytic Lymphohistiocytosis and Clostridium difficile Infection: A Diagnostic Dilemma
por: Boldig, Kimberly, et al.
Publicado: (2023)

The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review
por: Thandavaram, Abhay, et al.
Publicado: (2022)

Bezlotoxumab Therapy for Recurrent Clostridium difficile Infection in an Ulcerative Colitis Patient
por: Fein, Aaron, et al.
Publicado: (2022)

Risk for Clostridium difficile Infection After Allogeneic Hematopoietic Cell Transplant Remains Elevated in the Postengraftment Period
por: Dubberke, Erik R., et al.
Publicado: (2017)

Clostridium difficile Infection Complicated by Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia With Leukostasis and Sweet’s Syndrome
por: Landry, Ian, et al.
Publicado: (2021)

Multi-institution case–control and cohort study of risk factors for the development and mortality of Clostridium difficile infections in Japan
por: Takahashi, Masahiko, et al.
Publicado: (2014)

The Impact of Clostridium Difficile Infections on In-Hospital Outcomes of Venous Thromboembolism (Deep Vein Thrombosis or Pulmonary Embolism) Hospitalizations
por: Jhaveri, Khushali, et al.
Publicado: (2020)

Management of Recurrent Clostridium difficile Infection During Intensive Chemotherapy and Stem Cell Transplantation for Leukemia: Case with Literature Review
por: Zahid, Umar, et al.
Publicado: (2018)

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
por: Gerding, Dale N, et al.
Publicado: (2018)

Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection
por: Navalkele, Bhagyashri D, et al.
Publicado: (2018)

Factors Affecting the Decision Regarding COVID-19 Vaccination in the Saudi Public in the Central Region
por: Almutairi, Adel F, et al.
Publicado: (2022)

Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile
por: Alonso, Carolyn D, et al.
Publicado: (2018)

Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment
por: Shen, Judong, et al.
Publicado: (2020)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Handwashing with soap after potential faecal contact: global, regional and country estimates
por: Wolf, Jennyfer, et al.
Publicado: (2019)

Clostridium septicum Bacteremia As the Presenting Sign of Colon Cancer
por: Abraham, Andrew T, et al.
Publicado: (2023)

Efficacy of clotrimazole for the management of oral candidiasis: A meta-analysis of randomized clinical trials
por: Almangour, Thamer A., et al.
Publicado: (2021)

The Monoclonal Antitoxin Antibodies (Actoxumab–Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection
por: Džunková, Mária, et al.
Publicado: (2016)

Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
por: Prabhu, Vimalanand S, et al.
Publicado: (2017)

Clostridium Tetani Bacteremia From a Suspected Cutaneous Source
por: Kazadi, David, et al.
Publicado: (2022)

Is there a role of faecal microbiota transplantation in reducing antibiotic resistance burden in gut? A systematic review and Meta-analysis
por: Dharmaratne, Priyanga, et al.
Publicado: (2021)

Faecal volatile biomarkers of Clostridium difficile infection
por: Patel, Mitesh, et al.
Publicado: (2019)

Adherence to evidence-based guidelines for the management of pneumonia in a tertiary teaching hospital in Riyadh
por: Alessa, Mohammed, et al.
Publicado: (2023)

Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report
por: Almangour, Thamer A., et al.
Publicado: (2017)

Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial
por: Merrick, Blair, et al.
Publicado: (2020)

505. Bezlotoxumab Reduces Recurrence of Clostridium difficile Infection in Immunocompromised Patients: Early Experience at a Tertiary Care Center
por: Askar, Sally, et al.
Publicado: (2018)

Decreasing ICU-associated Clostridioides difficile infection through fluoroquinolone restriction, the FIRST trial: a study protocol
por: Safdar, Nasia, et al.
Publicado: (2021)

Fulminant Hepatic Failure and Fatal Cerebral Edema Following Clostridium perfringens Bacteremia: Case Report and Review of Literature
por: Shen, Alice, et al.
Publicado: (2017)

Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
por: Golan, Yoav, et al.
Publicado: (2017)

Randomised, double-blind, placebo-controlled, phase 2, superiority trial to demonstrate the effectiveness of faecal microbiota transplantation for selective intestinal decolonisation of patients colonised by carbapenemase-producing Klebsiella pneumoniae (KAPEDIS)
por: Pérez-Nadales, Elena, et al.
Publicado: (2022)

Calvarial Tuberculosis in Patient With Cervical Tuberculous Lymphadenitis: A Case Report
por: Almutairi, Rawan
Publicado: (2023)

Trends in Clostridioides difficile prevalence, mortality, severity, and age composition during 2003–2014, the national inpatient sample database in the US
por: Park, Sun O., et al.
Publicado: (2022)

Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection
por: Escudero-Sánchez, Rosa, et al.
Publicado: (2020)

Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience
por: Olmedo, María, et al.
Publicado: (2022)

Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection
por: Mileto, Steven J., et al.
Publicado: (2022)

Estimating the probability of demonstrating vaccine efficacy in the declining Ebola epidemic: a Bayesian modelling approach
por: Camacho, Anton, et al.
Publicado: (2015)

Lipid intensive drug therapy for sepsis pilot: A Bayesian phase I clinical trial
por: Guirgis, Faheem W., et al.
Publicado: (2020)

Discordant Clostridioides difficile diagnostic assay and treatment practice: a cross-sectional study in a tertiary care hospital, Geneva, Switzerland
por: Lenggenhager, Lauriane, et al.
Publicado: (2020)

Development of influenza-associated disease burden pyramid in Shanghai, China, 2010–2017: a Bayesian modelling study
por: Li, Jing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7drk3f57tfjrseqpviigvlgn33